

Company name **Avertto** * Website <https://www.avertto.com/>*

CEO name Dr. Hilla Ben Pazi*

CATEGORY: Health IT/Digital *

SESSIONS

- What can we do to make healthier aging a reality?

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Avertto is developing a patented telemonitoring medical device that detects changes in carotid pulse waves, providing early detection and treatment to prevent strokes before neurological damage occurs. The device integrates biological mimicry and Vagus Nerve Stimulation treatment, marking Avertto as a pioneer in this field. Targeting ICU in-patients initially, Avertto aims to redefine the standard of care for those at risk of stroke. The company's roadmap includes expanding to subcutaneous home telemonitoring, aligning with UNDP3 goals to prevent disability and reduce mortality from non-communicable diseases. The total addressable market for High-Acuity Beds in OECD countries is approximately \$14B.

o Core Technology What is the technology, its uniqueness, and its value proposition?

Avertto's technology is an insertable telemonitoring medical device that uses machine learning and signal analysis to detect large vessel occlusions with high accuracy (AUC=0.866). This device is unique in its ability to send timely alerts for early stroke intervention.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

The product is in the advanced stages of validation, with a blinded hospital study currently underway (model 201). Avertto's roadmap includes extending its application to home telemonitoring to further impact stroke prevention and care.

o Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Avertto's business strategy involves initial deployment in ICU settings followed by expansion into home telemonitoring. This approach is intended to establish a new standard in stroke prevention and leverage early successes to expand market presence and impact.

o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plan

R&D: Currently advancing with a blinded hospital study to validate the effectiveness of the stroke detection technology.

Preclinical / Clinicals: Collaborations for a second study are underway across multiple centers in Israel, Spain, and the USA.

Organizational Plans: Exploring strategic partnerships with industry leaders like Medtronic and Terumo.

Financial Plan: Regulatory steps are in progress for a Class 1 submission by Q3-24, with AEMPS registration already secured in Spain for CE certification. Multiple patent filings have been completed to protect the technology and its applications.